RESEARCH

Open Access

Characteristics and resource utilization of high-cost users in the intensive care unit: a population-based cohort study

Claudia Dziegielewski1*, Robert Talarico2, Haris Imsirovic2, Danial Qureshi2,3,4, Yasmeen Choudhri5, Peter Tanuseputro2,3,4,6, Laura H. Thompson2 and Kwadwo Kyeremanteng6,7

Abstract
Background: Healthcare expenditure within the intensive care unit (ICU) is costly. A cost reduction strategy may be to target patients accounting for a disproportionate amount of healthcare spending, or high-cost users. This study aims to describe high-cost users in the ICU, including health outcomes and cost patterns.

Methods: We conducted a population-based retrospective cohort study of patients with ICU admissions in Ontario from 2011 to 2018. Patients with total healthcare costs in the year following ICU admission (including the admission itself) in the upper 10th percentile were defined as high-cost users. We compared characteristics and outcomes including length of stay, mortality, disposition, and costs between groups.

Results: Among 370,061 patients included, 37,006 were high-cost users. High-cost users were 64.2 years old, 58.3% male, and had more comorbidities (41.2% had ≥3) when likened to non-high cost users (66.1 years old, 57.2% male, 27.9% had ≥3 comorbidities). ICU length of stay was four times greater for high-cost users compared to non-high cost users (22.4 days, 95% confidence interval [CI] 22.0–22.7 days vs. 5.56 days, 95% CI 5.54–5.57 days). High-cost users had lower in-hospital mortality (10.0% vs. 14.2%), but increased dispositioning outside of home (77.4% vs. 42.2%) compared to non-high-cost users. Total healthcare costs were five-fold higher for high-cost users ($238,231, 95% CI $237,020–$239,442) compared to non-high-cost users ($45,155, 95% CI $45,046–$45,264). High-cost users accounted for 37.0% of total healthcare costs.

Conclusion: High-cost users have increased length of stay, lower in-hospital mortality, and higher total healthcare costs when compared to non-high-cost users. Further studies into cost patterns and predictors of high-cost users are necessary to identify methods of decreasing healthcare expenditure.

Keywords: Intensive care unit, High-cost users, Costs, Healthcare expenditure, Critically ill

Background
Canadian health care expenditure is costly. It is expected to reach $264 billion in 2019, which translates to 11.6% of the gross domestic product (GDP) [1]. This is a particular concern within intensive care units (ICUs). The average daily cost for an ICU bed in Canada is $3592, which is threefold greater than the cost of a ward bed [2]. With the aging population and advances in medical care, ICU costs are projected to significantly rise over time, increasing by over 80% by 2026 [2–4]. This escalating demand for critical care emphasizes the need to identify cost-reducing strategies to ensure sustainability of the Canadian health care system.

*Correspondence: cldziegielewski@toh.ca
1 Department of Medicine, University of Ottawa, Ontario, Ottawa, Canada
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
A proposed intervention is to reduce spending on patients who account for a disproportionately large amount of health care spending, or high-cost users. This population has been well-described in the literature, where the top 5–10% of users consume up to 65% of hospital and nursing home costs [5–12]. In Canada, this translated to approximately $56 billion in 2016–2017 [13]. Within the ICU, the top 10% of users account for nearly 50% of the costs [14, 15]. In Canada, these patients were found to be younger, admitted with subarachnoid hemorrhage, acute respiratory failure, or complications of procedures, in contrast to high-cost users outside of the ICU, which have been found to be older with multiple medical comorbidities [6, 14, 16–19]. While several of these studies included a cost analysis, they largely limited their scope to inpatient costs in tertiary care centres [9, 14, 16, 18]. This prevents generalizability to different clinical settings, and excludes outpatient data from analysis. In this study, we described high-cost users in the ICU on a provincial level by conducting a population-based retrospective cohort study of Ontario residents. We evaluated health outcomes and analyzed cost patterns of high-cost users beyond the inpatient setting, and identified predictors of becoming a high-cost user. This information can provide insight into the characteristics of high-cost users and guide future work that can identify interventions that may reduce future healthcare expenditure.

Methods
Study design and population
We conducted a retrospective observational population-based cohort study in Ontario, Canada. The study population included all patients aged 18 years or older with at least one admission to an ICU from January 1, 2011 to March 31, 2018. The first ICU admission was used as the index admission. For patients with multiple ICU admissions within this timeframe, only the first ICU admission was included. Transfers to different hospitals were included in the same episode of care. Follow up data was obtained up to March 31, 2019. Patients were excluded if the date of admission or date of discharge were missing, the ICU LOS was <48 h, or if they were not OHIP (Ontario Health Insurance Plan) eligible during ICU admission or follow up (Additional Files Fig. 1).

Data sources and outcome variables
We conducted a population-based, retrospective cohort study using health administrative databases in Ontario, Canada. In Ontario’s single-payer healthcare system, all medically necessary health care services, physician, hospital, and demographic information for residents are recorded in these databases. Databases were linked and then anonymized at the individual level at the Institute for Clinical Evaluative Sciences (ICES), a non-profit custodian of provincial health data. ICES is funded by an annual grant from the Ontario Ministry of Health and Long-term Care. Patient demographics and deaths were obtained using the Registered Persons Database. Acute care hospitalizations, including information on outcome variables, were captured using the Discharge Abstract Database and Ontario Mental Health Reporting System. Comorbid conditions were presented using the Charlson comorbidity score, a score calculated based on a list of medical conditions a patient has within hospital records [20]. We identified complex chronic diseases among our cohort, using previously described methods (Additional Files Table 1) [21]. All other conditions were based on the presence of any one inpatient hospital diagnostic code, or two or more outpatient physician billing codes within a 2-year period, using relevant ICD, Version 9 (ICD-9) and ICD-10 codes. The National Ambulatory Care Reporting System was used to obtain information on emergency department (ED) visits. The OHIP Claims Database extracted data on physician fee-for-service claims for inpatient and outpatient services. The Ontario Drug Benefit Claims database tracked data on prescription medications dispensed to patients aged 65 years or older. The National Rehabilitation Reporting System was used for inpatient rehabilitation programs, the Continuing Care Reporting System for data on long-term care (i.e., nursing home) and complex continuing care use, and Home Care database for data on home care use. Codes can be found in Additional Files Tables 1, 2 and 3.

We obtained the total and sector-specific direct healthcare costs accumulated in the year following the date of the index ICU admission (including the admission itself). These were records of healthcare paid for by the Ontario Ministry of Health and Long-term Care (MOHLTC). We estimated the costs associated with each record by multiplying ICU length of stay by an average daily ICU cost per patient, using previously described standardized costing guidelines [22]. Briefly, we’ve taken a payer (MOHLTC) costing perspective, using person-level health care expenditures that accounts for data for health care utilization and cost information per use. Cost information for sectors (e.g., hospitals, complex continuing care, rehab) that have global budgets (e.g., by institution or by health region) were determined using a top-down approach through case-mix methodology. Sectors that have fee payments associated with each use (e.g., drug cost, or cost paid out to physician) had costs estimated directly. We expressed all costs in 2018 Canadian dollars, and past costs were adjusted for inflation using the yearly Consumer Price Index reported by Statistics Canada [23].
We derived outcome variables such as ICU and hospital LOS, inpatient procedures/interventions, and mortality. Patients were also followed up for up to 1 year post-high-cost admission to determine if there were recurrent ED visits, or re-admissions to hospital or ICU. We determined discharge disposition using a hierarchy approach (Additional Files Table 4).

We examined predictors of becoming a high-cost user, using variables that preceded index ICU admission. These included age, sex, income quintile, comorbidities, and ED and hospital visits prior to index ICU admission.

Patient groups
We separated patients into 1) patients with total healthcare costs in the upper 10th percentile, from index ICU admission to 1-year follow-up, or “high-cost” users, and 2) patients in the remaining 90%, or “non-high-cost” users. We chose to represent high-cost users as the upper 10th percentile based on previous studies using the same strategy [14, 15, 18].

Statistical analysis
We conducted statistical analysis using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA). We presented descriptive statistics as percentages or mean (with confidence intervals), as appropriate. We included standardized differences. We used a logistic regression to model the dichotomous outcome variable (whether an individual is a high- or non-high-cost user). The predictor variables of interest were age, sex, income quintile, Charlson score, number of ED and hospital visits before the index admission, as well as presence of the most prevalent comorbidities. P-values of < 0.05 were considered statistically significant.

Results
We identified a total of 370,061 patients admitted to the ICU based on inclusion criteria. Of these, 37,006 (10.0%) were classified as high-cost users and 333,055 (90.0%) represented non-high-cost users. Baseline patient characteristics for both groups are described in Table 1. High-cost users had a mean age of 64.2 years (95% confidence interval [CI] 64.0–64.3 years), compared to 66.1 years (95% CI 66.1–66.2 years) in the non-high-cost user group. There were 21,586 (58.3%) males in the high-cost group compared to 190,402 (57.2%) males in the non-high-cost group. Nearly 90% of high-cost users lived in urban areas, while 84.5% of non-high-cost users lived in urban areas. There were high rates of hypertension (52.8% vs. 48.9%), diabetes (38.2% vs. 30.6%), and cancer (30.9% vs. 29.8%) in the high-cost user group. The Charlson comorbidity index score was ≥3 in 41.2% of high-cost users compared to 27.9% in non-high-cost users.

Outcome variables including LOS, procedures, mortality, and discharge disposition are described in Table 2. Mean ICU and total hospital LOS was four times greater for high-cost users when compared to non-high-cost users (22.4 days, 95% CI 22.0–22.7 days; 59.9 days, 95% CI 59.1–60.6 days vs. 5.56 days, 95% CI 5.54–5.57 days; 13.8 days, 95% CI 13.8–13.9 days, respectively). Palliative care was involved more frequently for non-high-cost users (9.0% vs. 6.9%). High-cost users utilized higher rates of interventions, including invasive mechanical ventilation (63.4% vs. 29.8%), feeding tubes (17.5% vs. 3.0%), and dialysis (18.2% vs. 3.5%). High-cost users were more likely to be discharged to alternative placements other than home independently (77.4%), compared to non-high-cost users (42.2%). High-cost users had a lower mortality rate in hospital (10.0%) compared to non-high-cost users (14.2%). However, they had a higher mortality rate 1-year post discharge (27.0% vs. 25.2%). There were higher rates of ED visits both pre- (53.7% vs. 48.2%) and post-ICU admission (48.8% vs. 41.8%) for high-cost users.

Cost data from index ICU admission to 1-year follow up is summarized in Table 3, and represented as mean costs per average patient. Inpatient hospital costs were significantly higher for high-cost ($153,348, 95% CI $152,145–$154,552), compared to non-high-cost users ($25,620, 95% CI $25,547–$25,693). Inpatient costs accounted for the highest proportion of costs, more than 50% for both high-cost and non-high-cost users (Fig. 1). Costs for alternative disposition placements including complex continuing care and rehab were significantly higher for high-cost ($20,154, 95% CI $19,679–$20,628; $11,127, 95% CI $10,895–$11,358) vs. non-high-cost users ($809, 95% CI $791–$827; $1716, 95% CI $1693–$1740). Finally, mean total healthcare costs were substantially increased for high-cost users ($238,231, 95% CI $237,020–$239,442) compared to non-high-cost users ($45,155, 95% CI $45,046–$45,264). High-cost users accounted for 37.0% of total healthcare costs, equivalent to approximately $8.82 billion in total healthcare expenditure.

Multivariate logistic regression analysis was performed (Fig 2, Additional Files Table 5). Patients aged 80 and older (OR 0.50, 95% CI 0.48–0.52) were less likely to be high-cost users, compared to those under 50 years of age. Those with more than 1 (OR 1.58, 95% CI 1.53–1.63) or 2 comorbidities were very likely to be in the high-cost user group (OR 1.96, 95% CI 1.91–2.02). Of the top 5 comorbidities identified in this patient cohort, having a past medical history including renal failure (OR 1.75, 95% CI 1.70–1.80), osteoarthritis (OR 1.07, 95% CI 1.04–1.09), and hypertension (OR 1.06, 95% CI 1.03–1.08) were associated with high-cost user status. Both hospital admissions (OR 1.11, 95% CI 1.10–1.13) and ED visits (OR 1.02,
Table 1  Baseline patient characteristics of high-cost users and non-high-cost users admitted to the ICU

| Variable | High-cost (n = 37,006) | Non-high-cost (n = 333,055) | Standardized Difference |
|----------|------------------------|-----------------------------|-------------------------|
| Age, mean (95% CI) | 64.2 (64.0–64.3) | 66.1 (66.1–66.2) | 0.12 |
| Age categories, n (%) | | | |
| 18–49 | 6108 (16.5%) | 49,482 (14.9%) | 0.05 |
| 50–64 | 10,539 (28.5%) | 88,305 (26.5%) | 0.04 |
| 65–79 | 14,211 (38.4%) | 119,934 (36.0%) | 0.05 |
| 80+ | 6148 (16.6%) | 75,334 (22.6%) | 0.15 |
| Male, n (%) | 21,586 (58.3%) | 190,402 (57.2%) | 0.02 |
| Neighbourhood income quintile, n (%) | | | |
| Lowest | 9761 (26.4%) | 80,545 (24.2%) | 0.05 |
| Low | 8157 (22.0%) | 71,908 (21.6%) | 0.01 |
| Middle | 6945 (18.8%) | 65,409 (19.6%) | 0.02 |
| High | 6187 (16.7%) | 59,141 (17.8%) | 0.03 |
| Highest | 5783 (15.6%) | 54,845 (16.5%) | 0.02 |
| Missing | 173 (0.5%) | 1207 (0.4%) | 0.02 |
| Rurality, n(%) | | | |
| Urban | 32,944 (89.0%) | 281,388 (84.5%) | 0.13 |
| Rural | 3990 (10.8%) | 51,218 (15.4%) | 0.14 |
| Missing | 72 (0.2%) | 449 (0.1%) | 0.01 |
| Charlson comorbidity index score, n (%) | | | |
| 0–1 | 14,145 (38.2%) | 180,796 (54.3%) | 0.33 |
| 2 | 7603 (20.5%) | 59,499 (17.9%) | 0.07 |
| 3+ | 15,258 (41.2%) | 92,760 (27.9%) | 0.28 |
| Chronic conditions (by diagnosis), n (%) | | | |
| Hypertension | 19,527 (52.8%) | 162,938 (48.9%) | 0.08 |
| Diabetes | 14,145 (38.2%) | 101,914 (30.6%) | 0.16 |
| Cancer | 11,452 (30.9%) | 99,125 (29.8%) | 0.03 |
| Osteoarthritis | 10,814 (29.2%) | 92,475 (27.8%) | 0.03 |
| Renal Failure | 9277 (25.1%) | 44,061 (13.2%) | 0.30 |
| CHF | 8085 (21.8%) | 59,452 (17.9%) | 0.10 |
| CAD | 7041 (19.0%) | 73,569 (22.1%) | 0.08 |
| Mental Health | 6196 (16.7%) | 43,747 (13.1%) | 0.10 |
| COPD | 5372 (14.5%) | 46,505 (14.0%) | 0.02 |
| Arrhythmia | 4517 (12.2%) | 39,370 (11.8%) | 0.01 |
| Stroke | 2555 (6.9%) | 14,448 (4.3%) | 0.11 |
| Asthma | 2418 (6.5%) | 20,378 (6.1%) | 0.02 |
| MI | 1116 (3.0%) | 14,499 (4.4%) | 0.07 |
| Number of hospital admissions pre-ICU admission | | | |
| 0 | 22,576 (61.0%) | 233,725 (70.2%) | 0.19 |
| 1 | 7772 (21.0%) | 63,017 (18.9%) | 0.05 |
| 2+ | 6658 (18.0%) | 36,313 (10.9%) | 0.2 |
| Number of ED visits pre-ICU admission | | | |
| 0 | 17,151 (46.3%) | 172,423 (51.8%) | 0.11 |
| 1 | 8793 (23.8%) | 77,267 (23.2%) | 0.01 |
| 2+ | 11,062 (30.0%) | 83,365 (25.0%) | 0.11 |

Age is represented by mean years (confidence interval [CI]). The rest of the data is represented by n (%), where n = number of patients. Chronic conditions are considered active comorbidities within the last 2 years prior to index ICU admission. 

*CAD* coronary artery disease, *CKD* chronic kidney disease, *CHF* congestive heart failure, *COPD* chronic obstructive pulmonary disease, *MI* myocardial infarction
Prior to ICU admission were slightly associated with high-cost user status.

### Discussion

In this retrospective population-based cohort study, we describe the characteristics, outcomes, and cost patterns of high-cost users in the ICU that account for the upper 10th percentile of total costs to the healthcare system in Ontario, Canada. To our knowledge, there have been no prior studies describing high-cost users in the ICU on a provincial level and across multiple healthcare sectors. We found that high-cost users are younger, male, and come from lower income families. They have more comorbidities compared to non-high-cost users.
have a longer LOS in the ICU and hospital, lower in-hospital mortality rates, but higher rates of being discharged to placements other than to home independently. They were more frequently readmitted to ICU and acute care. High-cost users had a five-fold increase in total costs compared to non-high-cost users and despite only representing 10% of the cohort, accounted for more than one-third of total healthcare costs, which translated to $8.82 billion in total.

LOS has been previously well-described to be a significant driver of increased costs in the ICU [24–26]. This is supported by our study, which shows both ICU and total hospital LOS is four-fold greater for high-cost users. Furthermore, high-cost users have higher rates of interventions during their ICU admission. Invasive mechanical ventilation and dialysis are both costly procedures that often require ICU stay, and thus prolong LOS for patients in critical care [27, 28]. Taken together, the increased interventions and LOS likely contribute to significantly increased costs during admission. This correlates to our finding that inpatient costs contribute to more than 50% of total costs accrued by high-cost users.

| Variables                        | High-cost (n = 37,006)       | Non-high Cost (n = 333,055) | Standardized Difference |
|----------------------------------|------------------------------|----------------------------|-------------------------|
| Inpatient Hospital Costs         | $153,348 ($152,145–$154,552) | $25,620 ($25,547–$25,693)  | 1.50                    |
| Inpatient Mental Health Costs    | $2473 ($2265–$2682)          | $285 ($274–$296)           | 0.15                    |
| ED Costs                         | $1625 ($1604–$1646)          | $916 ($912–$920)           | 0.42                    |
| Outpatient Dialysis Costs        | $7585 ($7352–$7818)          | $397 ($379–$414)           | 0.43                    |
| Outpatient Cancer Costs          | $1613 ($1527–$1699)          | $774 ($759–$789)           | 0.12                    |
| Same Day Surgery Costs           | $662 ($5639–$686)            | $676 ($5669–$683)          | 0.01                    |
| CCC Costs                        | $20,154 ($19,679–$20,628)    | $809 ($791–$827)           | 0.58                    |
| LTC Costs                        | $2607 ($2517–$2698)          | $1057 ($1035–$1078)        | 0.20                    |
| Rehab Costs                      | $11,127 ($10,895–$11,358)    | $1716 ($1693–$1740)        | 0.56                    |
| Home Care Services Costs         | $6016 ($5883–$6150)          | $2016 ($1999–$2033)        | 0.40                    |
| Hospital Outpatient Clinic Costs | $3662 ($3628–$3696)          | $1516 ($1511–$1522)        | 0.81                    |
| Total FFS Visits                 | $22,176 ($22,019–$22,334)    | $6736 ($6721–$6752)        | 1.35                    |
| Non-FFS ED Visits                | $7.91 ($7.49–$8.33)          | $4.64 ($4.55–$4.72)        | 0.10                    |
| Non-FFS GP Visits                | $10.7 ($10.4–$11.0)          | $13.7 ($13.6–$13.8)        | 0.11                    |
| Non-FFS Medical Oncology Visits  | $105 ($97–$112)              | $48.2 ($46.9–$49.5)        | 0.10                    |
| Non-FFS Radiation Oncology Visits| $273.3 ($259–$286)           | $15.6 ($15.3–$15.9)        | 0.11                    |
| Other Non-FFS Visits             | $487 ($471–$503)             | $220 ($218–$222)           | 0.23                    |
| OHIP Non-Physician Costs         | $59.2 ($56.6–$61.8)          | $43.1 ($42.4–$43.9)        | 0.07                    |
| OHIP Lab Costs                   | $179 ($176–$182)             | $175 ($174–$176)           | 0.01                    |
| ODB Drug Costs                   | $4156 ($3984–$4328)          | $1952 ($1937–$1966)        | 0.18                    |
| Physician Capitation Costs       | $151 ($149–$153)             | $165 ($164–$165)           | 0.08                    |
| Total Healthcare Costs           | $238,231 ($237,020–$239,442) | $45,155 ($44,246–$45,264)  | 2.22                    |
**Fig. 1** Cost proportions for high-cost and non-high-cost users admitted to the ICU. **Notes:** Costs are represented as percentages of mean total costs. Inpatient costs include mean inpatient hospital, inpatient mental health, and ED (emergency department) costs. Physician costs are mean capitation costs. Outpatient costs include all mean outpatient dialysis, outpatient cancer, same day surgery, hospital outpatient clinic, total FFS and non-FFS visits, and OHIP non-physician costs. FFS = fee-for-service. Drugs/labs include mean OHIP lab and ODB drug costs. Disposition costs include mean complex continuing care, long term care, rehab, and home care services costs.

**Fig. 2** Forest plot displaying odds ratios of becoming a high-cost user in the ICU. **Notes:** Odds ratios are represented by squares. Horizontal error bars represent 95% confidence intervals. Age 18–49, lowest income quintile, and Charlson comorbidity score of 0–1 were used as the reference comparison group. CAD = coronary artery disease; ED = emergency department.
Disposition placements. Surprisingly, palliative care was less frequently involved in the care of high-cost users, although these patients appear to be more ill, comorbid, and frail and have higher out-of-hospital mortality. This highlights the importance of addressing goals of care early and re-evaluating which patients will benefit from critical care and aggressive interventions.

This study has identified several predictors of becoming a high-cost user. These include younger age, lower income, increased comorbidities, and prior hospital visits. Previous studies have shown conflicting reports on average age of high-cost users [14, 18, 35–37]. In our study, older patients, especially those age 80 and over, are less likely to be high-cost users. This is likely due to increased frailty and multi-morbidity predisposing them to earlier mortality and thus less likely to be in acute care long enough to accrue high costs [38, 39]. Socioeconomic status has been previously shown to be a significant predictor of becoming a high-cost user [37]. While preventing low income status is challenging, modifying health behaviours may help reduce medical illness that may predispose a patient to becoming a high-cost user. As expected, patients with more comorbidities are more likely to become high-cost users, as supported in previous studies [36, 40]. Common comorbidities such as renal failure and hypertension were associated with becoming a high-cost user, as patients are often frail, and develop complications of these conditions with lower mortality that may require critical care services [40, 41]. ED visits and hospital admissions prior to ICU admission were also associated with becoming a high-cost user, suggesting these patients are frequent users of the healthcare system. This highlights the importance of preventative care and having a primary care physician or specialist to closely follow and manage patients with several comorbidities.

Further studies should explore high costs in the ICU, and strategies of preventing patients from becoming high-cost users. This may include prospective trials that examine early palliative care approaches and multidisciplinary programs that integrate care. Palliative care has been shown to reduce ICU LOS and costs [42, 43]. Communication with patients and families on goals of care results in less frequent pursuit of ICU-level care while enhancing quality of care [44]. Furthermore, interdisciplinary care with several healthcare providers may help medically optimize patients and prevent hospital admissions, although literature is not available in the ICU setting [45–47]. While high-cost users are well-described in the literature, it is unclear how much of these costs are preventable. Some studies suggest that in the inpatient setting, less than 20% of costs may be preventable, but these were mostly limited to preventable ED visits and hospital re-admissions, which may not apply to several ICU admissions [37, 48]. This should be the focus of future studies, which could inform strategies in reducing costs while optimizing quality of care for patients in the ICU setting.

While this study involves a large population cohort that is robust and generalizable, there are several limitations. Firstly, we utilized health administrative data, which lacks certain detailed clinical variables and therefore limits the analysis of predictors of high-cost users. Admission diagnoses were not available in the database, and therefore information about which diagnoses are associated with higher costs could not be obtained. Functional data was not obtainable, which limits our understanding of the functional status of patients who become high-cost users. However, the higher proportion of high-cost users who are discharged to placements other than home without supports suggests decreased functional independence. While total costs were available, daily costs could not be obtained, which is likely variable depending on interventions and day of ICU stay. ODB captures drug costs for residents aged 65 years and older, which likely underestimates these costs; however, these costs are factored into the costing algorithm since hospital costs are top down. Cost analysis provided large category breakdown of costs; however, details such as specialist outpatient visits, or costs of certain interventions such as invasive mechanical ventilation, were not available. This information could be helpful to determine if patients being discharged from ICU receive appropriate follow up that may prevent future readmissions, or if certain interventions drive up costs [49]. However, the fact that there are less patients discharged home without care in the high-cost user group suggests a degree of functional impairment. Finally, the retrospective nature of this study allows association, but not causation, to be determined.

Conclusion
High-cost ICU patients in Ontario, Canada are younger, male, with increased comorbidities and lower mortality, and account for nearly 40% of total healthcare costs. Drivers of increased costs include LOS, increased interventions, and increased need for alternative disposition placement. Further research is necessary in identifying modifiable factors of becoming a high-cost user, and effective methods of preventing patients from becoming high-cost users, such as increased community supports, early palliative care, and interdisciplinary health teams. Together, these strategies may help reduce overall healthcare expenditure while improving patient outcomes.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12913-021-07318-y.

Additional file 1.

Acknowledgements
Not applicable.

Authors’ contributions
RT, HI, and DQ obtained and analyzed data. CD interpreted data and wrote the major part of the manuscript. YC contributed to the introduction section and Fig. 2. PT, LHT, and KK assisted in structuring the discussion. All authors read and approved the final manuscript.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary file. The dataset from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS. The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Declarations

Ethics approval and consent to participate
The study design and methodology were carried out in accordance with ICES guidelines and regulations, and received ethics approval from the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Canada. The use of data in this project was authorized under section 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a Research Ethics Board. All experimental protocols related to this study, as well as access of study data, were approved by ICES. ICES is a prescribed entity under Ontario’s Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of data in this project is authorized under section 45 and approved by ICES Privacy and Legal Office. Study data was anonymized before its use.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 2 ICES, University of Ottawa, Ottawa, Ontario, Canada. 3 Bruyere Research Institute, Ottawa, Ontario, Canada. 4 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 5 Department of Life Sciences, Queen’s University, Kingston, Ontario, Canada. 6 Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 7 Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Received: 22 February 2021 Accepted: 1 November 2021
Published online: 06 December 2021

References
1. National Health Expenditure Trends, 1975 to 2019. Canadian Institute for Health Information. Toronto; 2019.
2. Canadian Institute for Health Information. Care in Canadian ICUs. Toronto: Canadian Institute for Health Information, 2016.
3. Angus DC, Kelley MA, Schmitz RJ, White A, Popovich JJ. (COMPACCS) For the C on M for P and CCS. Current and projected workforce requirements for Care of the Critically ill and Patients with pulmonary disease: can we meet the requirements of an aging population? JAMA. 2000;284(21):2762–70.
4. Needham DM, Bronskill SE, Calinawan JR, Silbavid WJ, Pronovost PJ, Lau pars A. Projected incidence of mechanical ventilation in Ontario to 2026: preparing for the aging baby boomers. Crit Care Med. 2005;33(5):574–9.
5. Ideas and opportunities for bending the health care cost curve: advice for the government of Ontario. The Ontario Association of Community Care Access Centres (OACCAC), the Ontario Federation of Community Mental Health and Addiction Programs (OFCMHP) and. Canada: The Ontario Hospital Association (OHAta), 2010.
6. Rais S, Ardal S, Chechulin Y, Bains N, Malikov K. High-cost users of Ontario’s healthcare services. Healthc Policy. 2013;9(1):44–51.
7. Reid R, Evans R, Barer M, Sheps S, Kerlue K, McGrafl K, et al. Conspicuous consumption: characterizing high users of physician Services in one Canadian Province. J Health Serv Res Policy. 2003;8(4):215–24.
8. Roos NP, Shapiro E, Tate R. Does a small minority of elderly account for a majority of health care expenditures?: a sixteen-year perspective. Milbank Q. 1989;67(3–4):347–69.
9. Ronksley PE, Kobewka DM, McKay JA, Rothwell DM, Mulpuru S, Forster AJ. Clinical characteristics and preventable acute care spending among a high cost inpatient population. BMC Health Serv Res. 2016;16(165):1–10.
10. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. Can Med Assoc J. 2016;188(3):182–8.
11. Kim YJ, Park H. Improving prediction of high-cost health care users with medical check-up data. Big Data. 2019;7(3):163–75.
12. Lee NS, Whitman N, Vakharia N, Taksler GB, Rothberg MB. High-cost patients: hot-spotters Don’t explain the half of it. J Gen Intern Med. 2017;32(1):28–34.
13. Expenditure estimates for the Ministry of Health and Long-Term Care (2018–19). Government of Ontario. Canada: 2019.
14. Reardon PM, Fernando SM, Van Katwyk S, Thavorn K, Kobewka D, Tanuseputro P, et al. Characteristics, outcomes, and cost patterns of high-cost patients in the intensive care unit. Crit Care Res Pract. 2018:1–7.
15. Welton JM, Meyer AA, Mandelker L, Falkhy SM, Jarr S. Outcomes of and resource consumption by high-cost patients in the intensive care unit. Am J Crit Care. 2002;11(5):77–83.
16. Evans J, Kobewka D, Thavorn K, D’Egidio G, Rosenberg E, Kyeremanteng K. The impact of reducing intensive care unit length of stay on hospital costs: evidence from a tertiary Care Hospital in Canada. Can J Anesth. 2018;65(6):627–35.
17. Montgomery CL, Rolfs DB, Bagshaw SM. Frailty and the association between long-term recovery after intensive care unit admission. Crit Care Clin. 2018;34(4):527–47.
18. Rashid B, Kobewka DM, Campbell DJT, Forster AJ, Ronksley PE. Clinical factors contributing to high cost hospitalizations in a Canadian tertiary care Centre. BMC Health Serv Res. 2017;17(1):777.
19. Rosella LC, Kornas K, Yao Z, Manuel DG, Bornbaum C, Fransoo R, et al. Predicting high health care resource utilization in a single-payer public health care system: development and validation of the high resource user population risk tool (HRUpoRT). Med Care. 2018;56(10):61–9.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
21. Fernando SM, Qureshi D, Tanuseputro P, Fan E, Munshi L, Rochwer B, et al. Mortality and costs following extracorporeal membrane oxygenation in critically ill adults: a population-based cohort study. Intensive Care Med. 2019;45(11):1580–9.
22. Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person-level costing using administrative databases in Ontario. Working paper series. Toronto: health system performance research Network; 2013.

23. Statistics Canada. Consumer Price Index. 2020. Available: https://www.statcan.gc.ca/eng/subjects-start/prices_and_price_indexes/consumer_price_indexes [accessed June 20 2020].

24. Dasta JF, McLaughlin TP, Mody SH, Peich CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33(8):1266–71.

25. Kyeremanteng K, Wan C, D’Egidio G, Neillipovitz D. Approach to economic analysis in critical care. J Crit Care. 2016;36:92–6.

26. Chin-Yee N, D’Egidio G, Thavorn K, Heyland D, Kyeremanteng K. Cost analysis of the very elderly admitted to intensive care units. Crit Care. 2017;2:109.

27. Kaier K, Heister T, Motschall E, Hehn P, Bluhmki T, Wolkwitz M. Impact of mechanical ventilation on the daily costs of ICU care: a systematic review and Meta-regression. Epidemiol Infect. 2019;147:e314.

28. Karabatsou D, Tisoni M, Tsigou E, Boutzouka E, Katsoulas T, Baltopoulos G. Variable cost of ICU care, a Micro-costing analysis. Intensive Crit Care Nurs. 2016;35:66–73.

29. TEAM Study Investigators, Hodgson C, Bellomo R, Ferrey S, Bailey M, Bulh H, et al. Early Mobilization and Recovery in Mechanically Ventilated Patients in the ICU: A Bi-national, Multi-centre, Prospective Cohort Study. Crit Care. 2015;19(1):81.

30. Brummel NE, Bell SP, Girard TD, Pandharipande PP, Jackson JC, Morandi A, et al. Frailty and subsequent disability and mortality among patients with critical illness. Am J Respir Crit Care Med. 2017;196(1):64–72.

31. Hendin A, Tanuseputro P, Michael DS, Hsu AT, Smith GA, Begum J, et al. Frailty is associated with decreased time spent at home after critical illness: a population-based study. J Intensive Care Med. 2021;36(8):937–44.

32. Jutan N, Langlois L, Damiano N. Seniors and alternative level of care: building on our knowledge. Healthc Q. 2013;16(3):7–10.

33. Covinsky KE, Palmer RM, Fortinsky RH, Counsell SR, Stewart AL, Kresevic D, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003 Apr;51(4):451–8.

34. Walker D. Caring for our aging population and addressing alternate level of care. Toronto: Ontario Ministry of Health and Long-Term Care; 2011.

35. Qureshi D, Isenberg S, Tanuseputro P, Moineddin R, Quinn K, Meaney C, et al. Describing the characteristics and healthcare use of high-cost acute care users at the end of life: a Pan-Canadian population-based study. BMC Health Serv Res. 2020;20(1):997.

36. Rosella LC, Fitzpatrick T, Wodchis WP, Calzavara A, Manson H, Vivek G. High-cost health care users in Ontario, Canada: demographic, socioeconomic, and health status characteristics. BMC Health Serv Res. 2014;14:532.

37. Wammes JJG, van der Wees PJ, Tanke MAC, Westert GP, Jeurissen PPT. The association of frailty with Post-ICU disability, nursing home admission, and mortality: a longitudinal study. Chest. 2018;153(6):1378–86.

38. Ferrante LE, Pisani MA, Murphy TE, Gahbauer EA, Leo-Summers LS, Gill TM. The association of frailty with Post-ICU disability, nursing home admission, and mortality: a longitudinal study. Chest. 2018;153(6):1378–86.

39. Flaatten H, De Lange DW, Morandi A, Heyland D, D’Egidio G. The impact of palliative care consultation in the ICU on length of stay: a systematic review and cost evaluation. J Intensive Care Med. 2018;33(6):546–53.

40. Scheunemann LP, McDevitt M, Carson SS, Hanson LC. Randomized, controlled trials of interventions to improve communication in intensive care: a systematic review. Chest. 2011;139(3):543–54.

41. Statistics Canada. Leading causes of death, Total Population, By Age group. 2020. Available: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401 [accessed Nov 20 2020].

42. Aslakson RA, Curtis JR, Nelson JE. The changing role of palliative care in the ICU. Crit Care Med. 2014;42(11):2418.

43. Kyeremanteng K, Gagnon LP, Thavorn K, Heyland D, D’Egidio G. The impact of palliative care consultation in the ICU on length of stay: a systematic review and cost evaluation. J Intensive Care Med. 2018;33(6):546–53.

44. Scheunemann LP, McDevitt M, Carson SS, Hanson LC. Randomized, controlled trials of interventions to improve communication in intensive care: a systematic review. Chest. 2011;139(3):543–54.

45. Muratov S, Lee J, Holbrook A, Paterson JM, Guertin JR, Mbuagbaw L, et al. Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. CMAJ Open. 2019;7(3):E337–45.

46. Sherry M, Wolff JL, Ballreich J, Dugoff E, Davis K, Anderson G. Bridging the silos of service delivery for high-need, High-Cost Individuals. Popul Health Manag. 2016;19:421–8.

47. Tricco AC, Antony J, Ivers NM, Ashoor HM, Khan PA, Blondal E, et al. Effectiveness of quality improvement strategies for coordination of care to reduce use of health care services: a systematic review and Meta-analysis. CMAJ. 2014;186(15):E568–78.

48. de Oliveira C, Cheng J, Kurdyak P. Determining preventable acute care spending among high-cost patients in a single-payer public health care system. Eur J Health Econ. 2019;20(6):869–78.

49. McLaughlin AM, Hardt J, Canavan JB, Donnelly MB. Determining the economic cost of ICU treatment: a prospective ‘Micro-costing’ study. Intensive Care Med. 2009;35(12):2135–40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.